RxDoctor Payments DataLook up a doctor →

Patrick Simpson, MD

Interventional Cardiology · Pinehurst, NCNPI 1841234887

Payments from drug & device makers

$1,646,566in general payments, 2019–2025

Across 1,225 payments — averaging $1344.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$601K
  • American Regent$301K
  • Boehringer Ingelheim$174K
  • Lilly USA, LLC$160K
  • AstraZeneca$93K
  • Kowa Research Institute, Inc.$79K
  • plus $239K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC34$600,768
American Regent16$301,079
Boehringer Ingelheim166$173,968
Lilly USA, LLC172$160,006
AstraZeneca106$92,632
Kowa Research Institute, Inc.37$79,440
Novartis72$59,598
Boston Scientific172$51,455
Sanofi-aventis U.S. LLC40$36,586
Amgen23$35,169
Esperion Therapeutics, Inc.22$23,498
Regeneron Healthcare Solutions, Inc.22$10,456
Boehringer Ingelheim Pharma GmbH & Co.kg1$6,677
Merck13$3,194
Abbott31$1,426
Novo Nordisk5$1,334
Medtronic(2 entities)16$1,053
Abiomed16$959
Preventric Diagnostics, Inc.2$935
E.r. Squibb & Sons, L.L.C.31$614
Johnson & Johnson28$481
Pfizer26$480
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)27$468
Boehringer Ingelheim International GmbH3$431
Scpharmaceuticals Inc.8$393
Shockwave Medical, Inc10$377
Inari Medical, Inc.4$287
Actelion Pharmaceuticals US, Inc.12$278
Philips North America LLC15$255
Cardiovascular Systems Inc.7$253
Bayer13$207
Alnylam Pharmaceuticals Inc.6$205
Kiniksa Pharmaceuticals International, PLC9$186
Bridgebio Pharma, Inc.4$168
Opsens Inc.1$117
W. L. Gore & Associates, Inc.2$91
Chiesi USA, Inc.4$90
Atricure, Inc.4$85
Lexicon Pharmaceuticals, Inc.4$82
Cordis US CORP.3$61
Lundbeck LLC3$58
Daiichi Sankyo Inc.2$56
Amarin Pharma, Inc.3$51
Braemar Manufacturing, LLC1$46
Janssen Scientific Affairs, LLC1$38
Kiniksa Pharmaceuticals, Ltd.2$38
Edwards Lifesciences2$36
Kestra Medical Technology Services, Inc.2$34
Teleflex LLC2$34
Bristol Myers Squibb2$34
Irhythm Technologies, Inc.2$33
GSK2$30
Biomerieux Inc1$28
Angiodynamics, Inc.1$24
Cardinal Health 200 LLC1$22
Gilead2$22
Terumo Medical Corporation1$18
Akcea Therapeutics, Inc.1$18
Stryker1$18
Cardiva Medical, Inc.1$16

How this compares

$1,646,566 in reported general payments places this provider in the 95th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina →

Medicare billing

Part B allowed, 2024
$309,224
Medicare patients
1,348
Services billed
11,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Pinehurst

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →